Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO™ RESPIMAT ® (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the ...
RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & ...
DEAR DR. ROACH: I am a 73-year-old male with chronic obstructive pulmonary disease (COPD). I pretty much have it under control with medication, but I am still not able to do a whole lot, as I feel ...
RIDGEFIELD, Conn. and NORWALK, Conn., Nov. 17, 2022 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals Inc. welcomes the updated 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) ...
Please provide your email address to receive an email when new articles are posted on . Outcomes may vary among different fixed-dose combination inhalers for COPD ...
Boehringer makes significant investment to improve the affordability of and access to its full range of inhaler products for COPD and asthmaExpansive program builds on the company's century-long ...
AstraZeneca AZN announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rival Boehringer Ingelheim ...
Dear Dr. Roach: I am a 73-year-old male with chronic obstructive pulmonary disease (COPD). I pretty much have it under control with medication, but I am still not able to do a whole lot, as I feel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results